Member Login
  1. Stocks
    2. /
  2. AstraZeneca PLC (LSE: AZN)
    3. /

LSE:AZN (AstraZeneca PLC)

About AZN

AstraZeneca is a biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three main therapy areas - Respiratory, Inflammation and Autoimmunity (RIA), Cardiovascular and Metabolic Disease (CVMD) and Oncology – as well as in Infection and Neuroscience.
Financial Market Data copyright © 2024 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.

    • AstraZeneca PLC (LSE: AZN) Latest News

    Middle age senior woman sitting at the table at home working using computer laptop clueless and confused expression with arms and hands raised.
    Investing Articles

    Worried about a stock market crash? 2 FTSE 100 shares I’d consider buying anyway

    | Charlie Carman

    A stock market crash could be on the horizon. As a long-term investor, I continue to look for shares in…

    Read more »

    Investing Articles

    3 FTSE 100 stocks I’d buy with £20,000 now for the next 10 years

    | Manika Premsingh

    These FTSE 100 stocks are all part of Manika Premsingh’s portfolio, each bringing with them their unique long-term growth story. 

    Read more »

    Investing Articles

    3 FTSE 100 stocks I’d buy for growth in 2022

    | Roland Head

    FTSE 100 stocks can be fast growers too. Roland Head looks at three heavyweights with big growth forecasts, including an…

    Read more »

    Elevated view over city of London skyline
    Investing Articles

    3 UK shares to buy today with £3k

    | Rupert Hargreaves

    Rupert Hargreaves takes a look at the three UK shares he would acquire for his portfolio today as uncertainty grows.

    Read more »

    Investing Articles

    2 FTSE 100 stocks I’d buy in a stock market crash

    | Manika Premsingh

    This Fool believes that these two healthy FTSE 100 stocks have uncomfortably high prices right now, making them the perfect…

    Read more »

    Syringe and vial on blue background
    Investing Articles

    AstraZeneca shares: 3 reasons to consider buying now

    | Jon Smith

    Jon Smith explains the reasons why he's positive about AstraZeneca shares right now, despite the fall yesterday following results.

    Read more »

    Businessman touching on number 2022 for preparation
    Investing Articles

    1 FTSE 100 stock I’d buy with £1k for 2022

    | Manika Premsingh

    The FTSE 100 stock has been a rewarding one for this Fool in the past. And going by its results…

    Read more »

    A GlaxoSmithKline scientist uses a microscope
    Investing Articles

    Should I act on the GlaxoSmithKline share price or buy AstraZeneca instead?

    | Christopher Ruane

    Our writer considers whether the GlaxoSmithKline share price could make it an attractive addition for his portfolio, compared to rival…

    Read more »

    Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
    Investing Articles

    Why AstraZeneca stock is a buy right now

    | Ed Jones

    Fool contributor Ed Jones provides three reasons why he's bullish on AstraZeneca stock and is considering adding it to his…

    Read more »

    Investing Articles

    2022 dividend forecasts: HSBC, AstraZeneca, Glencore

    | Roland Head

    These FTSE 100 stocks are popular income picks, but how much will they payout in 2022? Roland Head looks at…

    Read more »

    Investing Articles

    1 FTSE 100 stock I wouldn’t miss buying in November

    | Manika Premsingh

    This FTSE 100 stock has seen a decline in share price in recent months. But that might be about to…

    Read more »

    Investing Articles

    2 FTSE 100 dividend stocks I’d aim to never sell

    | Kevin Godbold

    I wouldn't try to hold all my investments forever, but these two FTSE 100 dividend stocks both have many qualities…

    Read more »